Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Johnson & Johnson (NYSE: JNJ) Set to Acquire Abiomed (NASDAQ: ABMD) for $16.6 Billion or $380 per Share Plus CVR

Abiomed, Inc. (NASDAQ: ABMD) is engaged as a medical technology company, which is focused on providing support and resources to improve circulatory and oxygenation. Shares of the medical device company are surging 50% through afternoon trading on Tuesday, November 1, 2022. Over the past three months, Abiomed has seen average daily volume of 283,100 shares. However, volume of 4.63 million shares or dollar volume of around $1.75 billion, has already exchanged hands through afternoon trading.

Shares of Abiomed are rallying after the company announced it has entered into a definitive agreement to be acquired by Johnson & Johnson (NYSE: JNJ) in an all cash deal valued at $16.6 billion or $380 per share in cash. Abiomed shareholders will also receive a non-tradeable contingent value right (CVR), which entitles the investor to receive an additional $35 per share in cash if certain milestones are met.

The CVR milestones are broken down into three parts: $17.50 per share for net sales of Abiomed products exceeding $3.7 billion during JNJ’s fiscal Q2 2027 into fiscal Q1 2028; $7.50 per share payable upon FDA premarket application approval for the use of Impella products in STEMI patients by January 1, 2028; and $10 per share upon publication of a Class I recommendation for use of Impella products in high-risk PCI or STEMI patients with or without cardiogenic shock within four years from clinical endpoint publication dates but no later than December 31, 2029.

The acquisition helps Johnson & Johnson to bolster its MedTech division, particularly across cardiovascular disease treatment. Abiomed’s robust portfolio of first-in-kind treatments for coronary artery disease and heart failure, will provide JNJ with a innovative pipeline of tested technologies. JNJ says the acquisition will help to accelerate pro forma growth in the MedTech division as well as overall enterprise revenue growth for the medical giant.

Upon closing of the transaction, Abiomed Chief Commercial Officer Andrew Greenfield, has been appointed to serve as President of the subsidiary. The transaction is estimated to close before the end of the first quarter of 2023 and is subject to regulatory and customary closing conditions.

Disclosure: No position. Spotlight Growth has no relationships with any of the companies mentioned in this article and did not receive payment in any form for its creation. This is an opinion article and is not meant to be financial advise. We are not broker-dealers or investment professionals. Please conduct your own due diligence. For more information on our disclosures, please visit: https://spotlightgrowth.com/disclosures/

The post Johnson & Johnson (NYSE: JNJ) Set to Acquire Abiomed (NASDAQ: ABMD) for $16.6 Billion or $380 per Share Plus CVR appeared first on Spotlight Growth.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.